Imatinib Efficacy, Safety and Resistance in Iranian Patients with Chronic Myeloid Leukemia: A Review of Literature

Background: Imatinib is the gold standard in the treatment of chronic myeloid leukemia (CML) patients. Resistance to imatinib is interfering with patients’ responses and their survivals. Materials and Methods: We designed a systematic search to find relevant studies by applying appropriate keywords...

Descripción completa

Detalles Bibliográficos
Autores principales: Amouei, Asiyeh, Daeian, Nesa, Khezrnia, Seyedeh Sana, Mansouri, Ava, Hadjibabaie, Molouk
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Tehran University of Medical Sciences, Hematology-Oncology and Stem Cell Transplantation Research Center 2021
Materias:
Review Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381106/
https://www.ncbi.nlm.nih.gov/pubmed/34466210
http://dx.doi.org/10.18502/ijhoscr.v15i2.6042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8381106/
https://www.ncbi.nlm.nih.gov/pubmed/34466210
http://dx.doi.org/10.18502/ijhoscr.v15i2.6042

Ejemplares similares